Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 4/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24764834 | 0.91 | HDAC4 (0.33) | MCL1LMNADPP4ALDH1A1HDAC4 | |
| SCHEMBL10101586 | 0.79 | MAPT (0.39) | LMNADPP4DPP8DPP9ALDH1A1 | |
| SCHEMBL4083881 | 0.77 | CTSD (0.42) | LMNADPP4DPP8DPP9ALDH1A1 | |
| SCHEMBL21306793 | 0.77 | LMNA (0.37) | MCL1LMNAALDH1A1 | |
| SCHEMBL22851438 | 0.75 | LMNA (0.44) | MCL1LMNA | |
| SCHEMBL10245280 | 0.75 | MCL1 (0.41) | MCL1DPP4DPP8DPP9ALDH1A1 | |
| SCHEMBL1717828 | 0.75 | HMGCR (0.41) | LMNADPP4DPP8DPP9ALDH1A1 | |
| SCHEMBL41886 | 0.75 | — | — | |
| SCHEMBL22057051 | 0.74 | ALDH1A1 (0.34) | LMNAALDH1A1 | |
| SCHEMBL6283385 | 0.73 | KMT2A (0.41) | LMNADPP4DPP8DPP9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0818443-B1 | Mercaptoketones and mercaptoalcohols, a process for their preparation and their use as inhibitors of matrix metalloproteinases | AMERICAN CYANAMID CO (US) | 2001-12-05 | — | — | EP | claimed |
| US-5852213-A | Mercaptoketones and mercaptoalcohols and a process for their preparation | AMERICAN CYANAMID COMPANY (US) | 1998-12-22 | — | — | US | claimed |
| EP-0818443-A2 | Mercaptoketones and mercaptoalcohols, a process for their preparation and their use as inhibitors of matrix metalloproteinases | American Cyanamid Company (US) | 1998-01-14 | — | — | EP | claimed |
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| US-11760761-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760761-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11685722-B2 | Inhibition of Olig2 activity | Curtana Pharmaceuticals, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | Epizyme, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| EP-4006028-A1 | IRAK4 KINASE INHIBITOR AND PREPARATION METHOD THEREFOR | Zhuhai Yufan Biotechnologies Co., Ltd (CN) | 2022-06-01 | — | — | EP | disclosed |
| US-11242323-B2 | Inhibition of OLIG2 activity | Curtana Pharmaceuticals, Inc. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20210253535-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2021-08-19 | — | — | US | disclosed |
| WO-1998023588-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-06-04 | — | — | WO | disclosed |
| EP-0575844-B1 | Hydroxamic acid derivatives and pharmaceutical compositions thereof | HOFFMANN LA ROCHE (CH) | 1998-01-21 | — | — | EP | disclosed |
| EP-0818443-A2 | Mercaptoketones and mercaptoalcohols, a process for their preparation and their use as inhibitors of matrix metalloproteinases | American Cyanamid Company (US) | 1998-01-14 | — | — | EP | disclosed |
| EP-0763013-A1 | HYDROXYLAMINE DERIVATIVES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 1997-03-19 | — | — | EP | disclosed |
| WO-1995033709-A1 | HYDROXYLAMINE DERIVATIVES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 1995-12-14 | — | — | WO | disclosed |
| EP-0664284-A1 | Process for preparing carboxamides | F. HOFFMANN-LA ROCHE AG (CH) | 1995-07-26 | — | — | EP | disclosed |
| US-5304549-A | Control or prevention of degenerative joint diseases | HOFFMANN-LA ROCHE INC. (US) | 1994-04-19 | — | — | US | disclosed |
| EP-0575844-A2 | Hydroxamic acid derivatives and pharmaceutical compositions thereof | F. HOFFMANN-LA ROCHE AG (CH) | 1993-12-29 | — | — | EP | disclosed |
| EP-0497192-A2 | Amino acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1992-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | MCL1 471/4885LMNA 1762/4885DPP4 1575/4885 |
| US-20210253535-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | MCL1 66/4885LMNA 4459/4885DPP4 4474/4885 |
| US-11685722-B2 | Inhibition of Olig2 activity | GLI2, ING2, GMFG | MCL1 66/4885LMNA 4459/4885DPP4 4474/4885 |
| US-11760761-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | MCL1 58/4885LMNA 2102/4885DPP4 3077/4885 |
| US-11242323-B2 | Inhibition of OLIG2 activity | POU2F2, ING2, PAX2 | MCL1 97/4885LMNA 4437/4885DPP4 4567/4885 |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | EHMT2, BHMT, SHMT2 | MCL1 624/4885LMNA 3212/4885DPP4 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.